Kaiser Permanente, San Francisco Medical Center

San Francisco, California 94118-3100

5 studies enrolling now · 23 studies all time

What they study most

Acute Kidney Injury, Adnexal Mass, Advanced Solid Tumors, Advanced Unresectable or Metastatic Solid Malignancy, Antibiotic Stewardship, Asthma, Breast Cancer, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Squamous Non-Small Cell Lung, Coronary Artery Disease, Fallopian Tube Adenocarcinoma

Studies at this site

• Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. — Recruiting now
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer — Recruiting now
• Vancomycin Reduction Practices (VRP) in the NICU — Recruiting now
• NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial — Recruiting now
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib — Running, not enrolling
• Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy — Running, not enrolling
• PALbociclib CoLlaborative Adjuvant Study — Running, not enrolling
• Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC — Running, not enrolling
• Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms — Running, not enrolling
• Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms (TAMBE) — APPROVED_FOR_MARKETING
• The ShortCut™ Study Protocol — Completed
• A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response — Completed
• Study of a Gene Therapy Treatment for Hemophilia A — Withdrawn before enrolling
• A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma — Completed
• De-implementation of Outdated Colonoscopy Surveillance Interval Recommendations Among Patients With Low-risk Adenomas — Completed
• REDUCE LAP-HF TRIAL II — Running, not enrolling
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) — Completed
• Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy — Completed
• Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive — NO_LONGER_AVAILABLE
• Can Diet- and Exercise-Induced Weight Loss Improve Asthma Control in Adults? — Completed